Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.

Iain B McInnesProton RahmanAlice B GottliebElizabeth C HsiaAlexa P KollmeierSoumya D ChakravartyXie L XuRamanand A SubramanianPrasheen AgarwalShihong ShengYusang JiangBei ZhouYanli ZhuangDésirée van der HeijdePhillip J Mease

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2021)

In biologic-naive PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable risk-benefit profile through week 52.

Keyphrases

monoclonal antibody
rheumatoid arthritis
end stage renal disease
prostate cancer
ejection fraction
hiv infected
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
clinical trial
patient reported outcomes